EpimAb Biotherapeutics, a Shanghai-based biotech firm, has inked a licensing deal with Vignette for the development and commercialization of its T-cell engager (TCE) EMB-06 outside of Greater China. The agreement grants Vignette rights to EMB-06, a BCMA-targeting therapy, in regions excluding mainland China, Hong Kong, Macau, and Taiwan, with EpimAb retaining rights within Greater China. Vignette has agreed to an initial payment of $60 million to EpimAb, with the potential for up to $575 million in additional milestone payments linked to development, regulatory approval, and commercialization achievements, plus net sales commission.
EMB-06, a BCMA×CD3 bispecific antibody, has demonstrated significant clinical benefits in patients with multiple myeloma. This TCE molecule is the first to be developed by EpimAb using its proprietary T-cell engaging platform, which integrates the company’s FIT-Ig bispecific antibody platform with its independently developed CD3 binding domain library, leveraging EpimAb’s in-house drug discovery and antibody engineering expertise. – Flcube.com
